Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Published:2017-02 Issue:10068 Volume:389 Page:519-527
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Durie Brian G M,Hoering Antje,Abidi Muneer H,Rajkumar S Vincent,Epstein Joshua,Kahanic Stephen P,Thakuri Mohan,Reu Frederic,Reynolds Christopher M,Sexton Rachael,Orlowski Robert Z,Barlogie Bart,Dispenzieri Angela

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Treatment of newly diagnosed myeloma;Palumbo;Leukemia,2009

2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

3. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG);Kastritis;Leukemia,2009

4. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

5. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Engl J Med,2008

Cited by 718 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3—their sensing mediator—is tumor suppressive;Cell Death & Differentiation;2024-09-12

2. Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma;Blood Cancer Journal;2024-09-11

3. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation;Frontiers in Hematology;2024-09-11

4. Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma;American Journal of Hematology;2024-09-10

5. Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma;BMC Cancer;2024-09-09